Catherine Alix-Panabières: Epigenomic Profiling of Liquid Biopsy and Immunotherapy Resistance in Lung Cancer
Jan 31, 2025, 07:17

Catherine Alix-Panabières: Epigenomic Profiling of Liquid Biopsy and Immunotherapy Resistance in Lung Cancer

Catherine Alix-Panabières, Full Professor of Oncology at the Faculty of Medicine of the University of Montpellier, shared on LinkedIn:

“Today (30/01/2025) was the Kick-off Meeting of our European TRANSCAN project JTC 2023 called ‘EPILUNAR’!

Epigenomic Profiling of Liquid Biopsy and Immunotherapy Resistance in Lung Cancer

To identify and validate novel non-invasive epigenetic biomarkers and mechanisms of resistance associated to Immune Chekpoint Inhibitors – ICI (anti-PD1/anti-PDL1) in metastatic Non Small Cell Lung Cancer patients by characterizing the Epigenomic landscape of Liquid Biopsy, which will allow to personalize the management of Immunotherapy.”

Catherine Alix-Panabières: Epigenomic Profiling of Liquid Biopsy and Immunotherapy Resistance in Lung Cancer